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Abstract
Streptococcus agalactiae or Group B streptococcus (GBS) is an opportunistic 
human pathogen known for their invasive diseases caused in newborns, pregnant 
women, and nonpregnant adults. This pathogen even being an asymptomatic 
colonizer of adult humans, still they result in a broad range of disease manifesta-
tions starting from mild skin diseases to pneumonia, meningitis, and septicemia. 
Of the 10 GBS capsular types, the majority of invasive neonatal diseases are associ-
ated with the serotype III. GBS is a pathogen that has developed some strategies 
to resist host immune defenses. The formidable array of GBS virulence factors 
makes this bacterium at the forefront of neonatal pathogens. The involvement of 
bacterial components in the host-pathogen interaction of GBS pathogenesis and its 
related diseases is thought to be due to a variety of virulence factors expressed by 
Streptococcus agalactiae. Pathogenic factors of streptococcus promote infections by 
their coordinated activity. These factors/determinants initially get a stimulus by the 
communication between specific ligands and their respective receptors in a host-
pathogen interaction. These in turn activate adhesion and invasion mechanisms by 
mediating the attachment of pathogen via cell wall associated/secretory proteins, 
e.g., adhesins followed by their entry into the host cell eventually deciding their 
fate to live by activation of mechanisms like phagocytosis. These mediators/deter-
minants also modulate the immune responses by the host toward the pathogen. 
A number of new GBS surface-exposed or secreted proteins have been identified 
(GBS immunogenic bacterial adhesion protein, leucine-rich repeat of GBS, serine-
rich repeat proteins), the three-dimensional structures of known streptococcal 
proteins (αC protein, C5a peptidase) have been solved, and an understanding of 
the pathogenetic role of “old” and new determinants has been better defined in 
recent years. Recently, a 39kDa Invasion Inhibitory Factor (IIF) was isolated from 
GBS playing an important role in its invasion. A homogeneous non-toxic 39 kDa 
factor from the cytosol of GBS showing a homology with xenobiotic response 
element type transcriptional regulator protein adds another quill to the GBS protein 
panama, thus indicating that such protein molecules can be efficiently explored 
as suitable vaccine candidates. These observations add a novel aspect to bacterial 
pathogenesis where bacteria’s own intracellular protein component can act as a 
potential therapeutic candidate by decreasing the severity of disease thus promot-
ing its invasion inhibition.
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1. Introduction
Fry, in 1938 was the first to report Lancefield Group B β-hemolytic streptococci 
in three patients with puerperal sepsis [1]. After that, many sporadic cases were 
reported from different parts of the world in next 30 years but still this organism 
remained unexplored and unnoticed for most of the clinicians [2–4]. Then after 
reports of emerging GBS infections in neonates was followed up by increasing 
reports of infections in neonates followed by reports from pregnant women with 
localized uterine infection or chorioamnionitis commonly associated with bacte-
remia. The prognosis was found good with antimicrobial therapy. In other adults, 
the underlying infection often leads to fatality [5]. Till the 1990s, the scenario of 
GBS infection was the same, then after there was a substantial decline in reports of 
GBS infections. Current nomenclature designates polysaccharide antigens as type 
antigens with antigenically distinct types, Serotype Ia through IX, now are charac-
terized. Complete genome sequence of type III and V (most common and virulent 
serotypes) opened new avenues for identification of novel potential vaccine targets 
[6, 7]. Early concepts suggested a thick, rigid peptidoglycan layer external to the 
cytoplasmic membrane surrounded by concentric layers of cell wall antigens. In 
accordance with the Lancefield’s classification, there are different Group specific 
carbohydrates. These group specific carbohydrates were initially thought to be 
covered by a type-specific capsular polysaccharide (CPS), which was further 
deciphered by a study model showing evidences where group B carbohydrate and 
the CPS are linked independently to cell wall peptidoglycan [8]. Immunoelectron 
techniques using reference strains with homologous type-specific antisera reveals 
abundant CPS on Lancefield prototype strains Ia, II, III, IV, V, and VI, whereas less 
dense capsules are found on type Ib [9–11]. Studies also reveal that the expression of 
these capsular structures can be regulated by altering the cell growth. In addition, 
the ultrastructural studies using immunogold labeling and transmission electron 
microscopy shows that C protein also has a surface location along with GBS pilus-
like structures that extend from the bacterial surface [12, 13].
2. GBS disease outcomes
GBS is also known to be a leading cause of pneumonia and sepsis in newborns 
which can lead to fatal complications. As a resident of the maternal genital tract, 
during delivery, it may become a major cause of colonization and infection in the 
newborns. The neonate gets exposed to this organism through the birth canal 
through an ascending route in-utero via  the intact or ruptured membranes, thus 
leading to neonatal infections. A vertical transmission of 29–85% with a mean rate 
of approximately 50% was reported among newborns born to women from whom 
GBS was isolated either from their vagina or rectum or both during delivery. In 
contrast, only 5% of neonates are reported to be asymptomatically colonized 
at one or more sites during their first 48 h of life from mothers who are culture 
negative for GBS [14]. The risk of a neonate acquiring colonization by the vertical 
route correlates directly with the density of colonization (inoculum size). Majorly 
the transmission route is fecal oral. The GBS colonization acquired vertically or 
horizontally in neonates or young infants usually persists for weeks or months. 
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The mode of transmission likely is fecal-oral. Whether acquired by vertical or 
horizontal mode, colonization of mucous membrane sites in neonates and young 
infants usually persists for weeks or months [15].
It has also emerged as the third most common cause of infantile pyogenic 
meningitis [1, 2]. Exposure of pregnant females to this organism in developed and 
developing countries seem to be similar however, it is confusing to see an apparent 
lower incidence of GBS in less developed or developing countries. The data shows 
that in developed countries, neonatal GBS disease occurs 0.4–1.4 per 1000 live births 
with a fatality of up to 60%. Studies conducted in different centers during the 1990’s 
in developing nations fail to identify this pathogen [16]. Recent studies in Malawi, 
however had mixed results showing GBS as an important cause of neonatal sepsis 
[17] while very few studies are from India, showing 6.2% Early onset disease (EOD) 
burden and Nigeria still fail to report any disease burden [18–20] Several reasons are 
hypothesized that why the disease burden may be low in certain developing coun-
tries. First, there may be low maternal GBS colonization, which could then lead to 
low neonatal disease burden. Secondly, poor or less awareness among the pregnant 
mothers for GBS testing during their course of pregnancy. Few studies conducted 
in developing countries have reported quantitative maternal genital colonization, 
and those that have, reported a low prevalence of maternal GBS colonization [21]. 
In 2002, the implementation of guidelines to prevent early onset neonatal sepsis and 
screening at 35–37 week of gestation of pregnant women tremendously decreased the 
incidence of GBS infections [22]. Maternal postpartum sepsis and infective endocar-
ditis are also important complications associated with GBS infections [5, 23, 24]. In 
the recent years, osteomyelitis and septic arthritis often involving the knee, hip, or 
shoulder joints are also part of the GBS disease spectrum specially seen in adults [25].
2.1 Host-bacterial interactions in pathogenesis
Pathogenesis of any organism is a multistep, sequential invasion in the host cells 
mediated by specific molecules (may it be proteins, lipids or carbohydrate-protein 
complexes), which bring about the pathogen-host cell interaction by standard 
receptor-ligand interactions. Group B Streptococcus pathogenesis is also thought 
to be a multistep process [26]. In the ocean of many other pathogenic bacteria, 
GBS encodes a number of virulence factors for its pathogenesis. The colonization 
and breaching of mucosal surfaces by GBS thus allows its entry to normally sterile 
sites like blood stream, CNS and fetal membranes [27, 28]. The main virulence 
factor of GBS is thought to be pore forming toxins (Beta hemolysins/cytolysins 
and CAMP factor) and sialic acid rich CPS. Their virulence potential is because of 
its antiphagocytic properties [29]. Till date, nine serotypes (I to IX) on the basis of 
the capsular polysaccharide have been reported. The CPS also has a pivotal role in 
preventing complement activation, therefore does not influence adherence of GBS 
to epithelial cells but does reduce internalization [30]. Previous reports have shown 
that Serotype III accounts for approximately 50% of all neonatal infections as well 
as approximately 90% of cases of neonatal meningitis in US [31, 32]. Our earlier 
study has also shown that Type III isolates are more predominant as compared to 
other serotypes both in their invasiveness and biofilm formation [33]. Despite the 
advancement of the understanding about various virulence factors, their under-
standing on the regulation and use of these virulence tools has not yet been much 
explored. Thus, intensive investigations are done to elucidate the pathogenesis of 
GBS infection in neonates. The exclusive clinical features of GBS infection pose 
several questions that provide an agenda for hypothesis development (a hypotheti-
cal model) and experimental testing (Figure 1):
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1. How does the organism colonize pregnant women and gain access to the infant 
before or during delivery?
2. How do these bugs gain entry to the bloodstream and cross the blood–brain 
barrier?
3. How does GBS evade host innate immune defenses?
4. What factors of GBS induce sepsis?
5. Is there any role of intracellular factors of GBS in its pathogenesis?
6. How does the regulation of virulence factors occur during infection?
Some advancement in knowledge of pathogenesis has been achieved through 
development of cell culture systems and animal models. Many cell surface proteins, 
and other moieties including lipid moieties have been studied for their role in host-
pathogen interactions. However, not much about the cytosolic proteins of GBS is 
known. The group B streptococcal virulence factors defined to date, with proposed 
role in pathogenesis, are shown in Table 1 and discussed briefly below.
The process of human infection by group B Streptococcus (GBS) is complex and 
multifactorial. Adhesion and invasion of streptococci into the host cell involves 
a number of pathogen-host cell interactions (Figure 2). Their entry and survival 
inside the respiratory epithelial cells may represent a mechanism by which these 
bacteria gain access into the blood circulation [35–37]. Two main cell types, respira-
tory epithelial cells and resident alveolar macrophages, are encountered by GBS 
infecting the lung [38–40]. The former is the sentinel barrier for the streptococcal 
transcytosis into deeper tissues and thereafter into the bloodstream. Streptococcal 
surface-associated proteins are critically important in the host- pathogen relation-
ship as they can provide initial contact of the bacteria with its intended host before 
internalization [41]. An immunologic response is generated once GBS penetrates 
into lung tissue or bloodstream of newborn infant. This is followed by invitation to 
Figure 1. 
Hypothetical model of host-pathogen interaction of GBS.
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host phagocytic cells like neutrophils and macrophages leading to bacterial uptake 
and opsonization by specific antibodies in the presence of complement [42–44]. 
Primarily sialic acid derivatives i.e. sialylated Group B Streptococcal polysaccha-
ride capsule are the one to confront for opsonization mediated phagocytic killing 
followed by the other serotype specific epitopes of GBS capsular polysaccharide 
(CPS). It is also suggested that GBS may be chiefly a taxing human pathogen 
because its sialylated capsule has undergone selection to resemble host ‘self ’ thus 
avoiding immune recognition. Surface proteins of GBS have high efficiency to avoid 
Virulence factor Role in pathogenesis
Host cell adherence and invasion
C surface protein
Lipoteichoic acid
Fibrinogen receptor, FbsA
C5a peptidase
Surface protein Lmb
Spb1 surface protein
iagA gene
Adherence and invasion of epithelial cells
Attachment of epithelial cells
Attachment of epithelial cells
Adherence and invasion of epithelial cells
Attachment of epithelial cells
Invasion of epithelial barriers
Promotes blood brain barrier invasion
Host tissue insult
Beta-hemolysin/cytolysin
Hyaluronate lyase
CAMP factor
Damage and spread through tissues
Promotes spread through host tissues
Direct tissue injury
Molecules in immune evasion
Exopolysaccharide capsule
C5a peptidase, ScpP
CAMP factor
Serine Protease, CspA
Fibrinogen receptor, FbsA
C Protein
Beta-Hemolysin/cytolysin
Superoxide dismutase
Carotenoid pigment
Dlt operon genes
Penicillin binding protein Ia
Blocks opsonophagocytic clearance
Inhibits neutrophil recruitment
Impairment of antibody function
Blocks opsonophagocytosis
Blocks opsonophagocytosis
Blocks opsonophagocytosis
Impairment of phagocyte killing
Impairment of oxidative burst killing
Impairment of oxidative burst killing
Interferes with antimicrobial peptides
Interferes with antimicrobial peptides
Molecules as inflammatory mediators
Cell wall LTA
Cell wall peptidoglycan
Beta Hemolysin/cytolysin
Cytokine activation
Cytokine activation
Triggers iNOS and Cytokine release
Table 1. 
GBS virulence factors and their role in pathogenesis.
Figure 2. 
Scanning electron micrograph (SEM) of (a) GBS, (b) GBS adhering to and invading into A549 cells (courtesy: 
Ohri et al. [34]).
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opsonophagocytosis along with CPS. C protein or its components resist phagocytic 
killing and inhibits its interaction with complement or IgG [45]. A cell surface pro-
tease CspA, targets host fibrinogen producing adherent fibrin like cleavage products 
that coat the bacterial surface and interfere with opsonophagocytic clearance [46].
With a big pool of virulence factors encrypted by GBS, it has been confirmed to 
adhere to a variety of eukaryotic cellular structures. ECM proteins including lam-
inin, fibronectin, fibrinogen, cytokeratin and plasminogen facilitates interaction 
with host-cell surface integrins thus promoting the entry of GBS into the varied 
host cells [41]. The initial step of adherence is thought to be mediated by a number 
of bacterial moieties such as laminin binding proteins, C5a peptidase, glyceralde-
hyde phosphate dehydrogenase, α-enolase and lipoteichoic acid [47]. In addition to 
adherence facilitating moieties, alpha C protein and invasion associated gene (iagA) 
are important molecules in the process of GBS invasion in host cells. Genome-wide 
phage display technique revealed a fibronectin-binding property associated with 
the surface-anchored group B streptococcal C5a peptidase, ScpB [48]. This dual 
functionality of ScpB was confirmed by decreased fibronectin binding of isogenic 
ScpB mutants and the direct interaction of recombinant ScpB with solid-phase 
fibronectin [48, 49]. Similar targeted mutagenesis studies showed that adherence 
of GBS to laminin involves a protein adhesin called Lmb [50], repetitive motifs 
within the surface-anchored protein FbsA mediates attachment to fibrinogen [51], 
and binding to human keratin 4 is carried out by the serine rich repeat domain 
protein Srr-1 [52]. Recently, GBS were revealed to express filamentous cell surface 
appendages known as pili [36]. Pili mediate GBS resistance to AMP’s (antimicrobial 
peptides) and also aid in its attachment to the host cells. Two genetic loci have 
been found on GBS genome, which are responsible for pilus like structures. Among 
eight sequenced GBS genomes, not all genomes contain both loci [53]. One of these 
islands includes genes encoding PilB, an LP(x)TG motif–containing protein that 
polymerizes to form a pilus backbone and is the major structural component of 
GBS pili, along with accessory pilus proteins PilA and PilC [53, 54]. Isogenic GBS 
mutants lacking PilA or PilC showed decreased adherence to epithelial cells, but not 
mutants lacking the PilB backbone. In addition, the crystal structure of PilC reveals 
a specific IgG-like fold domain (N2) required for epithelial cell binding [54]. Upon 
bacterial binding to the host cell receptors, recruitment of host-cell actin to the 
site of bacterial entry has been observed [55, 56]. However, there are some studies 
which have shown that certain bacterial surface proteins like type III CPS and the 
N-terminal region of the alpha C protein partially mask the specific components 
of GBS that are critical for adherence/invasion of eukaryotic cells [29, 57, 58]. Thus 
decreasing the adherence and invasion efficiency of GBS to host cells. Similarly, 
Burnham et al., showed prior treatment of the epithelial cells by exogenous addition 
of phosphoglycerate kinase (PGK, a cell surface and a cytosolic protein of GBS) 
inhibited GBS internalization [40]. PGK as a major outer surface protein of GBS 
which showed a similar inhibitory effect using saccharomyces derived PGK in Type 
V GBS invasion. PGK from other sources like Candida albicans and Schistosoma 
mansoni has also been used to study host-pathogen interactions specifically invasion 
and adherence mechanisms [58–60]. Boone et al. [57] showed GBS-PGK released 
from the bacterial cell binds to plasminogen and actin. These secreted proteins 
demonstrate an interaction between the bacterial protein and their host cell recep-
tors [61]. However, as reported by Hulse et al. [62] Type III capsular polysaccharide 
is also reported to attenuate invasion if pre-incubated with the host cells. A similar 
study was performed with Lactoferrin, an antimicrobial peptide, showing its 
invasion inhibitory activity on a broad range of organisms including streptococcus 
[61]. There are many other studies which report that cell surface molecules can also 
be used to inhibit adherence and invasion in bacteria. A recent published study 
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from our lab has reported the role of a cytosolic protein in inhibition of invasion 
of GBS into eukaryotic epithelial cells [34]. A 39 kDa invasion inhibitory factor 
(IIF) isolated from cytosol of GBS showed almost 70–80% reduction in invasion 
as compared to the crude cytosolic fractions indicating an anti-internalization 
mechanism. N-terminal sequence showed its homology with a xenobiotic response 
element(XRE) type transcriptional regulator protein. This family of transcription 
factors controls various metabolic functions in the bacteria, thus emphasizing on 
its probable role in pathogenesis as well [63]. Studies like these raise a question as to 
how an organism can itself contain or manufacture such a factor which can inhibit 
its own mechanism of pathogenesis thus indicating that bacteria’s own components 
can also play an important role in its adherence and invasion process.
As most pregnant women have low concentrations of type-specific IgG in their 
sera, immunization of women during adolescence, before pregnancy, or in late 
pregnancy (i.e., early third trimester) would be the best approach for immuno-
prophylaxis [64]. In view of the substantial disease burden in nonpregnant adults, 
targeted adult immunization (e.g., diabetics or adults “65 years old) also is an 
attractive prevention strategy. GBS serotypes Ia, III, and V are reported to be most 
invasive forms to cause disease in infants and adults followed by serotypes Ib and 
II that account for 75–85% of infections [65–68]. The production of a trivalent or 
a pentavalent conjugate vaccine is technically achievable. The cost of developing 
suitable vaccines, although substantial, is considerably less than the death, disabil-
ity, and treatment associated with these infections [69, 70]. In 2014, World Health 
Organization convened the first meeting for consultation on GBS vaccine develop-
ment, focusing on the GBS maternal immunization program, which was aimed at 
reducing infections in neonates and young infants worldwide [70].
3. Conclusion
Despite the availability of the genome sequence of GBS, advances have been 
made in deciphering the various facets of molecular mechanisms involved in disease 
pathogenesis. This has taken our knowledge a step forward in knowing the pivotal 
role of certain molecular targets which can be explored as target vaccine candidates. 
Though, GBS being a commensal and an adaptable organism which adjusts its niche 
according to the environment, it fine tunes its gene expression for its pathogenesis 
paradigms. Thus, it becomes more imperative to understand how this pathogen 
responds to its external environment to appropriately express this large repertoire 
of factors for colonization or invasion of the host tissue targets, which is still under 
infancy. As it is commonly said ‘Prevention is better than Cure’, thus to prevent GBS 
disease the physicians, public health officials, parents, and patients must join hands 
and campaign for pregnant women, neonates and young infants, and at-risk adults.
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